Cardarine (GW501516) — complete guide: effects, dosage and risks
01 Mar
Cardarine is one of the most misunderstood substances in the training world. It is often sold under the label “SARM”, but is not actually a selective androgen receptor modulator at all. GW501516 — as it is called in the research literature — is a PPARδ receptor agonist with a completely different mechanism of action. Even so, it is consistently grouped with SARMs in stores, forums and discussions, as the target audience and uses overlap. We go through what cardarine actually does, how it is dosed, what risks the research has identified and why the substance never reached the market as a medicine.
Mechanism of action — PPARδ, not the androgen receptor
Cardarine activates the PPARδ receptor (peroxisome proliferator-activated receptor delta), a nuclear receptor that regulates gene expression linked to fat metabolism, energy production and endurance. It is a fundamentally different mechanism compared to SARMs such as Ostarine or RAD-140, which act via the androgen receptor and affect muscle building and hormone balance.
When PPARδ is activated, the cells’ ability to oxidize fatty acids as an energy source increases. In practice, this means that the body shifts its energy metabolism from glucose to fat, even during physical exertion. The effect has been likened to “reprogramming the body’s fuel preference” — a concept that captured enormous interest in both the pharmaceutical industry and endurance sports.
GW501516 was originally developed by GlaxoSmithKline and Ligand Pharmaceuticals in the 1990s. The primary area of research was metabolic syndrome — a combination of obesity, high blood fats, insulin resistance and high blood pressure that affects hundreds of millions of people globally. In animal models, cardarine showed impressive results: dramatically improved blood lipids, increased fat burning and markedly improved endurance. Mice treated with GW501516 were able to run up to 70% farther on a treadmill — a figure that immediately caught the attention of the sports world.
Cardarine effects — what users report
The effects of cardarine can be divided into two main categories: metabolic changes and endurance enhancement. Both are well documented in animal studies and anecdotally confirmed by users, but human data from controlled studies is limited.
Fat burning is the effect that drives most of the interest. Users consistently report that body fat percentage drops faster during a cardarine period compared to exercise and diet alone. The effect is explained by the increased fatty acid oxidation — the body simply burns more fat for fuel, especially during low- to moderate-intensity physical activity. It is not about appetite suppression (as with GLP-1 drugs) but about a changed metabolic preference at the cellular level.
Endurance is noticeably improved. Runners, cyclists and crossfit practitioners describe a significant increase in time to exhaustion and a faster recovery between work sessions. The mechanism is supported by animal studies showing that PPARδ activation increases the number of type I muscle fibers (endurance fibers) and improves mitochondrial function. WADA banned cardarine back in 2009 under the category of “hormonal and metabolic modulators” — a decision that in itself confirms that the substance’s performance-enhancing potential was taken seriously.
Blood lipids are improved in the limited human studies that have been conducted. In a phase II trial in dyslipidemia patients, GW501516 lowered triglycerides by 30% and raised HDL cholesterol by 16% after just eight weeks. These metabolic improvements were the original reason the substance was developed — and they remain its most solid scientific basis.
An important aspect that distinguishes cardarine from SARMs: it does not affect hormone production. Cardarine suppresses neither testosterone, LH nor FSH, which means that no PCT (post cycle therapy) is needed after a cardarine period. You can use it on its own without worrying about hormonal down-regulation — or combine it with other SARMs where it contributes to fat burning and endurance without increasing the hormonal load.
Cardarine dosing — protocol and practice
Cardarine has never been approved as a drug, which means there are no officially established dosage guidelines. The doses used in the research and training community are based on extrapolation from animal studies and phase II human studies, combined with decades of anecdotal experience.
The standard dose that most experienced users apply is 10–20 mg per day, taken orally. Cardarine has a half-life of 16–24 hours, making a single daily dose sufficient. Many prefer to take it in the morning or 1-2 hours before exercise to maximize the endurance-enhancing effect during the session.
Period length varies, but 8–12 weeks is the most common protocol. Longer periods occur but lack support in human data and increase the potential risk of side effects. Shorter periods of 4–6 weeks may be sufficient for those who are only looking for a temporary fat-burning effect before, for example, a competition or the summer.
Escalation is generally not considered necessary for cardarine. Most people start directly on their target dose without dose titration, as the side effects are typically mild and not dose-dependent in the same way as for hormonal substances.
Cardarine side effects and risks — the critical question
And here we come to the question that must be addressed honestly: why did GlaxoSmithKline stop developing a substance with such promising metabolic effects?
The answer lies in long-term studies on rodents. When mice and rats were treated with GW501516 at high doses for extended periods (often lifelong in animal studies), they developed tumors in multiple organs, including the liver, stomach, thyroid, and bladder. The study results were not published in full by GlaxoSmithKline but were leaked and subsequently confirmed by independent researchers.
Context is important here. The doses in the carcinogenic rodent studies were dramatically higher than what humans typically use — often 10-100 times higher relative to body weight. The treatment time also corresponded to the entire life span of the animals. This does not mean that the risk can automatically be dismissed at lower doses and shorter periods, but it gives some proportion. The problem is that we simply don’t know where the safe limit is in humans — the long-term studies that could answer the question have never been conducted and probably never will be conducted.
The limited human studies available (phase I and phase II, up to 12 weeks) reported no serious side effects. However, these studies were short, included relatively few participants, and were not designed to capture cancer risks. That the substance was well tolerated for three months says little about safety at six months or a year.
Commonly reported short-term side effects at typical doses (10–20 mg) include headache in some users, temporary increased body temperature, and sometimes mild gastrointestinal distress. These are generally mild and transient. It is the potential long-term risks that constitute the real worry cloud.
Cardarine in Sweden — legal status and availability
Cardarine is not classified as an anabolic steroid or narcotic in Sweden. It is also not an approved drug. It is in a legal gray area — similar to that of many SARMs — where the substance is not expressly prohibited from possession for personal use but is also not regulated or quality assured.
As a research chemical, cardarine can be purchased online from specialist suppliers. However, the quality variation between suppliers is significant. Without regulation there are no guarantees of purity, correct dosage or absence of contamination. Third-party testing via independent labs (for example, HPLC analysis) is the only way to verify that the product contains what the label promises. Choose suppliers who publish analysis results — and be skeptical of those who don’t.
In organized sports, cardarine has been strictly banned by WADA since 2009. Doping tests can detect GW501516 and its metabolites for several weeks after the end of use. It is not a substance to experiment with if you compete in any form of organized sport.
.entry-content